14 July 2022
Allen & Overy advises Bayer on the sale of Nebido™ to Grünenthal Share on Facebook Share on Twitter Share on LinkedIn Share on Xing Share on WeChat Print
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Dr Nicolaus Ascherfeld Lead | Allen & Overy | Partner | Corporate/M&A | Hamburg |
| Dr Sebastian Remberg Lead | Allen & Overy | Counsel | Corporate/M&A | Not stated |
| Dr Markulf Behrendt | Allen & Overy | Partner | Employment | Hamburg |
| Dr Udo H Olgemöller | Allen & Overy | Partner | Public Law | Frankfurt |
| Dr Jens Matthes | Allen & Overy | Partner | IP | Düsseldorf |
| Marie-Luise von Buchwaldt | Allen & Overy | Counsel | Corporate/M&A | Hamburg |
| Anna Kräling | Allen & Overy | Senior associate | IP/IT | Düsseldorf |
| Stefanie Günther | Allen & Overy | Senior associate | Public Law | Frankfurt |
| Louisa Graubner | Allen & Overy | Associate | Corporate/M&A | Hamburg |
| Kornelius Lotha | Allen & Overy | Associate | Corporate/M&A | Hamburg |
| Merle Herrmann | Allen & Overy | Associate | Employment | Hamburg |
| Dario Barbato | Allen & Overy | Other | Corporate/M&A | Hamburg |
Stated terms
- Stated value
- EUR 500m (up to EUR 500 million)
- What the figure measures
- Total transaction value
- Client
- Bayer AGSell-side
- Counterparties
- Grünenthal (Buy-side)